Supplemental Figure 8: The cardioprotective effects of AICAR administration. (A) Blood pressure in 12 month old males. Mean±SEM; t-test; n = 5-6. (B) Experimental timeline of AICAR injections, measurements, and terminal procedure. (C) Thin-layer chromatography of cardiac lipid extracts from mice administered vehicle or AICAR. n = 3. (D) Left ventricular fatty acid profile in WT/HCM mice ±AICAR. Mean±SEM; ANOVA; n = 3. (E) Immunoblot analysis of CD36 (normalized to GAPDH) in pooled cardiac lysates from mice administered vehicle or AICAR. (F-H) Cardiac caspases3/9 and β-actin immunoblot. Mean±SEM; ANOVA; n=3. (I) Effect of AICAR on ventricular glycogen levels (normalized to wet tissue weight). Mean±SEM; ANOVA; n=3-5. (J) Effect of AICAR on post-prandial circulating insulin, glucose, NEFA (non-esterified fatty acid) and TG levels. Values were normalized to pre-injection baseline levels. Mean±SEM; ANOVA; n=4-9. *Significantly different (P ≤ 0.05) from WT before AICAR-treatment.